• Biodesix Highlights Clinical Data Demonstrating the Potential of EarlyCDT Lung Blood Test to Improve Early Detection of Lung Cancer

    September 9, 2019 Download the PDF   -Positive Results From 12,209-Person Study at 2019 World Conference on Lung Cancer-   Boulder, CO, and BARCELONA, September 9, 2019 – Biodesix®today highlighted positive clinical data from Oncimmune’s EarlyCDT Lung® blood test, which harnesses the power of the immune system to detect evidence of the body’s natural response to cancer. The technology can detect ... Read more
  • Biodesix Adds Dr. Charles Watts to Board of Directors

    August 26, 2019  Boulder, Colo. -August 7, 2019 – (Business Wire) – Read more
  • Biodesix Adds Dr. Robert Georgantas III to Executive Leadership Team

    August 26, 2019   -Distinguished Genomic Scientific Leader Joins Lung Cancer Diagnostic Solutions Company-   BOULDER, Colo. Biodesix, Inc.a leading lung cancer diagnostic solutions company, today announced the appointment of Robert W. Georgantas III Ph.D. as the company’s Senior Vice President (SVP) of Research and Translational Science. Dr. Georgantas’ research career in genetic, epigenetic, and transcriptomic immunology and oncology clinical biomarkers ... Read more
  • Biodesix, Immodulon Collaborating on Pancreatic Cancer Biomarkers

    August 6, 2019 NEW YORK – Biodesix, Boulder, Colo, said today that it is collaborating with immune-oncology firm Immodulon Therapeutics to identify proteomic markers linked to pancreatic cancer. Under the agreement, the companies will use Biodesix’s Diagnostic Cortex biomarker discovery platform to analyze the circulating proteome of advanced pancreatic cancer patients treated with Immodulon’s candidate immunotherapy IMM-101. “From this collaboration ... Read more
  • Biodesix Reaches Agreement to Deliver Next-Generation Sequencing Assay for Blood-Based Companion Diagnostic Solutions in Cancer

    July 9, 2019 Download the PDF   -Initiative Aims to Develop Lung Cancer Diagnostic Testing with FDA Premarket Approval Classification Using Thermo Fisher Scientific’s Oncomine Assay Components-  Boulder, CO, July 9, 2019 – Biodesix, Inc. the leader in blood-based lung cancer diagnostic solutions, today announced it has entered into an agreement with Thermo Fisher Scientific. The agreement is designed to ... Read more
  • Biodesix to Acquire Oncimmune in the United States

    June 28, 2019 Download the PDF   -Acquisition of US Laboratory and Lung Nodule Malignancy Risk Test-  Boulder, CO, June 28, 2019 – Biodesix, Inc. today announced that it will extend the company’s blood-based lung cancer diagnostic portfolio with acquisition of Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the United States. The United Kingdom-based company’s U.S. operations, ... Read more
  • Biodesix Previews Data for Osimertinib Resistance and Precision of Liquid Biopsy at AACR

    March 26, 2019 Download the PDF -New Data to be Presented at American Association for Cancer Research Annual Meeting-  Boulder, CO, March 26, 2019 – (GLOBE NEWSWIRE)–Biodesix® will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib, and on the precision of liquid biopsy in comparison to ... Read more
  • Biodesix VeriStrat Data Demonstrate Independent Prediction of Immunotherapy Outcomes for NSCLC Patients

    March 19, 2019 Download the PDF -New Front-Line Data Presented at Multidisciplinary Thoracic Cancer Symposium-   Boulder, CO and SAN DIEGO, March 14, 2019 – Biodesix® today presented new data demonstrating that the VeriStrat® test is predictive of outcomes for patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint ... Read more
  • MRM Proteomics and Biodesix Partner to Develop Precision Lung Cancer Diagnostics

    January 28, 2019 Download the PDF – Deal Underscores Need for Proteomic Data to Enable Precision Medicine– MONTREAL and BOULDER, Colo., Jan. 28, 2018 (BUSINESS WIRE) MRM Proteomics Inc. and Biodesix® have inked a partnership to create novel assays to answer critical clinical questions within the lung cancer continuum of care. Under terms of the deal, MRM ... Read more
  • Biodesix Test Predicts Response to Atezolizumab in Lung Cancer

    November 12, 2018 Download the PDF – Researchers Present New Data from Blood-Based Proteomic Test in Biomarkers and Immune Monitoring at SITC 2018 –   BOULDER, Colo., Nov. 12, 2018 (GLOBE NEWSWIRE) Researchers with Biodesix® and Genentech, a member of the Roche Group, today presented findings on a test designed to ... Read more